About amivantamab
EGFR-MET bispecific antibody
Used for
- Treats certain advanced non-small cell lung cancers with specific EGFR gene changes, alone or with other medicines.
Usual adult dose
Intravenous dosing varies by cancer type, treatment combination, body weight, and treatment phase; follow the prescribed oncology regimen.
Common side effects
- Infusion-related reactions
- Rash and nail problems
- Swelling, including around the eyes or legs
- Fatigue, nausea, or constipation
Important warnings
- Infusion reactions can be severe; monitoring and premedication are required.
- Can cause serious skin reactions and eye problems.
- Can cause lung inflammation; report new or worsening breathing symptoms promptly.
- Pregnancy should be avoided during treatment and for three months afterward.
Pregnancy
May harm an unborn baby. Effective contraception is recommended during treatment and for three months after the last dose.
Breastfeeding
Avoid breastfeeding during treatment and for three months after the last dose.
Interactions
- Other anticancer medicines may increase side effects; combination treatment requires oncology supervision.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.